丙酸诺龙 | 7207-92-3

• 物质功能分类: 分析化学 - 标准品 - 法医和兽医标准品
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 丙酸诺龙
• 中文别名: 甲醇中丙酸诺龙
• 英文名称: nandrolone propionate
• 英文别名: [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate
• CAS: 7207-92-3
• 化学式: C₂₁H₃₀O₃
• mdl: MFCD00198408
• 分子量: 330.467
• InChiKey: LGRKCTFWUWAKON-RRFJAZBJSA-N

物化性质

• 熔点：
  55-60°
• 比旋光度：
  D23.5 +58° in chloroform (Rao)
• 沸点：
  453.6±45.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)
• 溶解度：
  DMF：30mg/mL； DMSO：30mg/mL；乙醇：2mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.809
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1(b)
• 危险品标志：
  Xn
• 安全说明：
  S22,S24/25
• 危险类别码：
  R40,R48
• 危险品运输编号：
  UN 2811
• 包装等级：
  III
• 危险类别：
  6.1(b)

反应信息

• 作为反应物：
  描述：

  丙酸诺龙 、 环己醇 生成
  参考文献：
  名称：

  Process for the preparation of enolethers of delta4-3-ketosteroids

  摘要：

  公开号：

  US03019241A1
• 作为产物：
  描述：

  诺龙 、 丙酸酐 生成 丙酸诺龙
  参考文献：
  名称：

  19-nortestosterone acylates and 3-enol acylates thereof

  摘要：

  公开号：

  US02798879A1

文献信息

• METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION
  申请人：Meehan Alan

  公开号：US20110092470A1

  公开（公告）日：2011-04-21

  A method of treating male sexual dysfunction or erectile dysfunction by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction.

  本文描述了一种通过使用5α还原酶抑制剂和睾酮补充剂来治疗男性性功能障碍或勃起功能障碍的方法。该方法还涉及使用5α还原酶抑制剂和睾酮补充剂与其他用于治疗勃起功能障碍的药物一起使用，包括PDE V抑制剂；AGE（高级糖基化终产物）破坏剂；α1受体阻滞剂；α1A拮抗剂；α2拮抗剂；多巴胺激动剂；多巴胺D4激动剂；黑色素细胞激素激动剂；催产素激动剂；前列腺素；自由基清除剂；旋转酶抑制剂；aviptadil；硝酸甘油；以及GPCR激动剂，用于治疗男性性功能障碍或勃起功能障碍。
• Method of treating men with testosterone supplement and 5alpha reductase inhibitor
  申请人：MERCK SHARP & DOHME (I.A.) CORP.

  公开号：EP2371367A1

  公开（公告）日：2011-10-05

  A method of treating Alzheimer's disease, Parkinson's disease, sexual dysfunction or erectile dysfunction in a man by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction.

  描述了一种通过服用 5α 还原酶抑制剂和睾酮补充剂来治疗阿尔茨海默病、帕金森病、性功能障碍或男性勃起功能障碍的方法。该方法还涉及将 5α 还原酶抑制化合物和睾酮补充剂与另一种治疗勃起功能障碍的药物一起使用，包括 PDE V 抑制剂；AGE（高级糖化终产物）分解剂；α 1 阻滞剂；α1A拮抗剂；α2拮抗剂；多巴胺激动剂；多巴胺D4激动剂；黑皮质素激动剂；催产素激动剂；前列腺素；自由基清除剂；腐胺酶抑制剂；阿维他地尔；硝酸甘油；以及治疗男性性功能障碍或勃起功能障碍的GPCR激动剂。
• Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
  申请人：Redwood Pharma AB

  公开号：US10799446B2

  公开（公告）日：2020-10-13

  A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

  本发明公开了一种雌激素和雌激素类似物或其他雌激素受体调节剂的局部应用制剂，用于治疗原发性或继发性干眼综合征（又称角结膜炎（KCS））。优选制剂包括脂质、脂质体、聚合物或水性或非水性载体中的 17-β-estradiol 及其衍生物，用于眼表组织的局部治疗，特别是作为缓释或微剂量制剂。这些制剂还可用于治疗可能发生 KCS 的其他病症，如屈光手术后和角膜移植患者。
• Pharmaceutical composition for alleviating the violence of a mammal comprising nortestosterone derivatives
  申请人：——

  公开号：US20040058898A1

  公开（公告）日：2004-03-25

  The present invention relates to a pharmaceutical composition for alleviating the violence, sublimating the nature and stimulating the appetite of a mammal, including an ostrich, a cat, a dog, a goat, a horse, a lion, a tiger, a leopard, an elephant and pet animals, which violently behaves, cries and does not take feed, comprising an effective amount of one or more metabolic nortestosterone derivative selected from the group consisting of 17&bgr;-hydroxy-4-estren-3-one (19-nortestosterone) and ester derivatives of 17&bgr;-hydroxy-4-estren-3-one (19-nortestosterone) which is administered to said mammal in need of treatment for such conditions.

  本发明涉及一种药物组合物，用于减轻包括鸵鸟、猫、狗、山羊、马、狮、虎、豹、象和宠物动物在内的哺乳动物的暴躁行为、升华天性和刺激食欲，这些哺乳动物暴躁、哭闹和不进食，该药物组合物包含一种或多种有效量的代谢去甲睾酮衍生物，这些衍生物选自17&bgr;-羟基-4-雌烯-3-酮（19-去甲睾酮）和17&bgr;-羟基-4-雌烯-3-酮（19-去甲睾酮）的酯衍生物组成的组；-羟基-4-雌烯-3-酮（19-去甲睾酮）和 17&bgr;-羟基-4-雌烯-3-酮（19-去甲睾酮）的酯类衍生物组成的组中的一种或多种代谢去甲睾酮衍生物，将其施用给需要治疗此类病症的哺乳动物。
• Pharmaceutically acceptable carrier for ophthalmic compositions
  申请人：Du Mee P. Charles

  公开号：US20060210645A1

  公开（公告）日：2006-09-21

  A pharmaceutically acceptable carrier for ophthalmic compositions useful in treating or alleviating the symptoms of dry eye syndrome, elevated intra-ocular pressure, age-related maculopathy or age-related macular degeneration.

  一种药学上可接受的载体，用于治疗或缓解干眼症、眼压升高、老年性黄斑病变或老年性黄斑变性症状的眼科组合物。